Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 8/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24040182 | 0.90 | GNAI3 (0.43) | GNAI3GNAO1GNAI1GPR84FFAR1 | |
| SCHEMBL21024634 | 0.89 | GNAI3 (0.42) | GNAI3GNAO1GNAI1GPR84FFAR1 | |
| SCHEMBL24398569 | 0.89 | GPR84 (0.41) | GPR84FFAR1 | |
| SCHEMBL20372808 | 0.87 | ALDH1A1 (0.39) | GNAI3GNAO1GNAI1EPHX2 | |
| SCHEMBL26465066 | 0.80 | GAA (0.46) | GNAI3GNAO1GNAI1 | |
| SCHEMBL19661521 | 0.78 | GPR84 (0.40) | GPR84FFAR1 | |
| SCHEMBL20626619 | 0.77 | DPP4 (0.41) | EPHX2 | |
| SCHEMBL24182542 | 0.76 | JAK3 (0.39) | — | |
| SCHEMBL13772760 | 0.76 | HPGD (0.45) | — | |
| SCHEMBL22622606 | 0.75 | PIK3CD (0.43) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, FRK | GNAI3 819/4885GNAO1 1250/4885GNAI1 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.